The studies on the effects of reduced GH-action in humans leading to a significantly reduced cancer burden, have been highlighted by the pioneering studies noting an almost non-existent cancer and diabetes incidence in Laron syndrome patients [87] and in GHD patients[88]. This evidence concerns the gene GH1 and diabetes mellitus.